MedTrace Logo

Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib

NCT03629691 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 187

Last updated 2018-08-16

No results posted yet for this study

Summary

The primary end point was progression-free survival (PFS), secondary end points included duration of locoregional control (LRC), overall survival (OS), quality of life and safety. For metastatic lung cancer, LRC is the local control of metastatic lung tumor here.

Conditions

Interventions

OTHER

lung cavitation

apatinib treated patients developed lung cavitation

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-01
Primary Completion
2018-05-19
Completion
2018-05-19

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03629691 on ClinicalTrials.gov